Vitamin D3 for Life

Live Enlightened

Article

Structure and transport role of vitamin D binding protein: Study Summary

Previous related pageStructure and transport role of vitamin D binding protein: Full StudyNext related pageStudy Summary: Pharmacokinetics of a single, large dose of cholecalciferol
Study at a glance

How does vitamin D-binding protein carry vitamin D in the blood?

This page explains how vitamin D-binding protein carries forms of vitamin D in blood. It combines studies of the protein’s structure, mouse experiments, kidney studies and one rare human case. These different types of evidence help explain the carrier’s role and its limits.

What happened to mice that could not make vitamin D-binding protein?

The protein attaches strongly to vitamin D forms and helps keep them in the blood for longer. Mice unable to make this protein had very low total vitamin D blood measurements. They remained broadly normal when vitamin D supply was adequate. When their diet contained less vitamin D, they developed hormone and bone changes sooner.

What did kidney studies and the rare human case show?

Kidneys can recover vitamin D attached to the carrier protein, rather than losing it in urine. This does not mean every organ uses the same process. A woman who could not make the carrier protein had extremely low total vitamin D measurements but normal blood calcium. Her case showed that some vitamin D functions remained despite the missing carrier.

Do total blood levels show all vitamin D activity in tissues?

The carrier helps maintain a supply of vitamin D in blood, but is not required for every vitamin D effect. Mouse experiments and complete loss of the human protein are unusual situations. They do not tell us the size of effects from common inherited differences. Total blood levels do not directly measure all vitamin D activity in tissues.

Read the full article below ↓

Vitamin D-binding protein (DBP) is the dominant high-affinity carrier for circulating vitamin D metabolites, but its physiological role is broader than transport from one place to another. Structural, knockout, receptor-pathway and rare-human evidence show that DBP creates a stable circulating reservoir, slows loss of metabolites and can participate in specialised tissue uptake. The same evidence also shows an important limit: DBP is not absolutely required for every biological action of vitamin D. See Full Study.

What is DBP structurally?

Human DBP is encoded by the GC gene and belongs to the albuminoid protein family. X-ray crystallography resolved a three-domain protein with the main vitamin D-binding pocket in domain I. That molecular structure provides a physical explanation for DBP’s high-affinity binding of vitamin D metabolites rather than leaving the carrier relationship as an inference from blood measurements alone.

Why does high-affinity binding matter?

High-affinity binding allows a large total circulating pool of 25-hydroxyvitamin D [25(OH)D] to coexist with a very small free fraction. In this sense DBP acts as a reservoir and buffer. The broader carrier system is explained in Vitamin D Transport Proteins, while Plasma Transport of Vitamin D Metabolites: Evidence Synthesis gives the narrower evidence-based view of how that carrier system shapes plasma persistence.

Targeted DBP-knockout mice show the consequence directly. They have very low total circulating vitamin D metabolites, yet remain broadly normal when vitamin D supply is adequate. DBP markedly prolongs the serum half-life of 25(OH)D and helps maintain stable stores. When dietary vitamin D is restricted, animals without DBP develop secondary hyperparathyroidism and skeletal changes more quickly, showing that the carrier provides reserve when supply falls.

Can cells use vitamin D while it is DBP-bound?

In the renal proximal tubule, yes. Cubilin and megalin participate in receptor-mediated retrieval of DBP-bound 25(OH)D. Dysfunction of this pathway causes urinary loss of vitamin D metabolites and abnormal vitamin D metabolism. This is a strong exception to a simplistic rule that only free vitamin D can ever become available to cells. The organ-level setting is covered in Vitamin D and Kidneys.

The mechanism is tissue-specific. It should not be projected onto every organ. A deeper mechanistic treatment is available in Cellular uptake and intracellular handling of vitamin D metabolites: Full Evidence Review, while Vitamin D Transport and Tissue Delivery: Evidence Synthesis places renal retrieval within the wider question of how carrier-bound and free pools reach different tissues.

What does rare human DBP deficiency show?

A woman with homozygous deletion of the GC gene had no detectable circulating DBP and extremely low total vitamin D metabolite concentrations. Despite that, she maintained normocalcaemia and meaningful vitamin D function. The case confirms in humans that total serum concentration is partly a property of the binding-protein reservoir rather than a direct meter of all tissue action.

What did the different experiments establish?

The evidence is strongest because the studies perform different jobs. Crystallography establishes the physical binding site. The mouse knockout tests what disappears when DBP itself is removed and shows reduced circulating reserve, shorter metabolite persistence and greater vulnerability to deficiency. Cubilin-megalin work establishes a renal route by which a protein-bound metabolite can be recovered rather than lost. The rare human GC deletion then shows that the extreme low-total/highly altered-binding state is possible in people as well as animals.

No single experiment proves the whole transport model. Their agreement across molecular structure, causal knockout, receptor-mediated uptake and human genetics is what makes the overall interpretation strong.

What should the evidence not be taken to mean?

  • DBP is not absolutely required for every vitamin D effect.
  • Renal megalin-cubilin uptake is not proof that all tissues use the same pathway.
  • Rare complete GC deletion and mouse knockout are extreme perturbations and do not quantify ordinary common human polymorphisms.
  • A lower total 25(OH)D concentration caused by reduced DBP does not necessarily imply an equally large reduction in free vitamin D or tissue action.

The central point is that DBP changes the size, stability and handling of the circulating vitamin D pool. That is why the relationship described in Free vs Total Vitamin D Explained cannot be understood without transport physiology.

The practical implication is not that serum measurements should be ignored. It is that transport context changes what a measured concentration represents. A large DBP-bound reservoir supports persistence and buffering, while tissue-specific uptake mechanisms determine whether some bound substrate can be actively recovered. The distinction also helps explain why Vitamin D Status vs Vitamin D Effect is broader than any single serum number.

Primary evidence and publication details

A structural basis for the unique binding features of the human vitamin D-binding protein. Verboven C, Rabijns A, De Maeyer M, Van Baelen H, Bouillon R, De Ranter C. Nature Structural Biology. 2002;9:131-136.

Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein. Safadi FF, Thornton P, Magiera H, et al. Journal of Clinical Investigation. 1999;103:239-251.

Cubilin dysfunction causes abnormal metabolism of the steroid hormone 25(OH) vitamin D3. Nykjaer A, Dragun D, Walther D, et al. Proceedings of the National Academy of Sciences USA. 2001;98:13895-13900.

Vitamin D-Binding Protein Deficiency and Homozygous Deletion of the GC Gene. Henderson CM, Fink SL, Bassyouni H, et al. New England Journal of Medicine. 2019;380:1150-1157.

Related reading

Original sources